From a recent paper:
Methods
We enrolled consecutive patients presenting to our community hospital with recent onset AF into a protocol, which called for rhythm control with procainamide and if unsuccessful electrical cardioversion and discharge home. We compared this prospective cohort with matched historical controls. Primary outcome was admission rate. We also compared ED conversion rates and lengths of stay (LOS). We reported 30-day data on the study group including ED recidivism, recurrent AF, outpatient follow-up, and any important adverse events.
Results
Fifty-four patients were enrolled in the study group with 4 being admitted compared with 30 of 50 in the historical control group. Ninety-four percent of the study group converted compared with 28% in the historical control. Both hospital and ED LOS were significantly shorter for the study group. Six patients had recurrent AF, and 4 of those returned to the ED.
The patient had to have had onset of
atrial fibrillation within 48 hours. In patients without cardiac
awareness this would be difficult to determine. If there was any
doubt on the part of the treating physician the patient was excluded.
This makes it look so nice and easy but
I think anticoagulation should enter the discussion. There are two
aspects of anticoagulation to consider: prior to conversion (either
immediately pre-prodedure or for a month or so prior) and after
conversion, for a month or more, due to the thromboembolic risk
resulting from atrial stunning post conversion, as well as the
possibility that AF will recur. For people who have been in AF for
less than 48 hours the widespread belief (and the tacit assumption in
this article) is that you don't need to worry about it. The patients
in this study, apparently, were not anticoagulated, given that the
body of the paper states that no new medications were prescribed at
ER discharge. However, the question deserves more nuance than it is
usually given. There is actually some controversy around the
decision not to anticoagulate in cases of AF of less than 48 hours
duration. The evidence to guide clinicians is not the greatest. The
guideline statement is very vague (one can consider
anticoagulation, before and/or after, or not) and is in the form of a
IIb recommendation. The condition for that statement is that the
patient be deemed low risk. Up to Date expresses concern
about this no anticoagulation approach and suggests it only for
patients at very high bleeding risk or those who are CHADS VASC zero.
Some of their experts recommend anticoagulation before and/or after
(for a month) even for those low risk patients. This is an
under-discussed elephant in the room.
No comments:
Post a Comment